Phase II Study of BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
Conditions: Diabetic Foot Ulcer Interventions: Biological: BB-101 Sponsors: Blue Blood Biotech Corp. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Conditions: Metastatic Breast Cancer Interventions: Drug: ESG401; Drug: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician ' s Choice) Sponsors: Shanghai Escugen Biotechnology Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
Conditions: Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma Interventions: Drug: SNC115 injection Sponsors: Shanghai Simnova Biotechnology Co.,Ltd.; Shanghai Chest Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients
Conditions: Corneal Erosion Interventions: Drug: SHJ002; Other: Vehicle Sponsors: Sunhawk Vision Biotech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Conditions: Systemic Lupus Erythematosus; Systemic Sclerosis; Inflammatory Myopathy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Sjogren ' s Syndrome Interventions: Other: YTS109 Sponsors: China Immunotech (Beijing) Biotechnology Co., Ltd.; Shanghai Changzheng Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
FDA Approves Clinical Trial for GFH925 Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
SHANGHAI, April 19, 2024. GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 22, 2024 Category: Pharmaceuticals Source Type: clinical trials
Single-center Clinical Study on the Safety and Effect of Bronchoscopic Cryotherapy in Patients With Chronic Cough
Conditions: Chronic Cough Interventions: Procedure: General treatment; Procedure: Cryotherapy Treatment Sponsors: Guangzhou Medical University; Ningbo SensCure Biotechnology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Multi-organ Responses to CHronic Physical Activity and INactivity
Conditions: Sedentary Behavior; Metabolic Syndrome; Age-related Cognitive Decline; Age-Related Sarcopenia Interventions: Behavioral: Decreased Physical Activity; Behavioral: Increased Physical activity Sponsors: University of Nottingham; Biotechnology and Biological Sciences Research Council Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Conditions: Herpes Zoster Interventions: Biological: HZ Vaccine (IN001); Biological: Placebo; Biological: Shingrix Sponsors: Shenzhen Shenxin Biotechnology Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)
Conditions: HPV16+ Squamous Cell Carcinoma Interventions: Drug: HB-200; Other: Placebo Sponsors: Memorial Sloan Kettering Cancer Center; Hookipa Biotech GmbH; Naveris Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
Conditions: Japanese Encephalitis Sponsors: Liaoning Chengda Biotechnology CO., LTD Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
BiVictriX Announces FDA Orphan Drug Designation and Completion of FDA INTERACT Meeting for BVX001 in the Treatment of Acute Myeloid Leukemia
Alderley Park, 17 April 2024– BiVictriX Therapeutics plc (AIM: BVX), a biotechnology company developing novel, next-generation bispecific Antibody Drug Conjugates (bxADCs) which are designed to offer substantially improved cancer cell... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 17, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
Conditions: Triple-negative Breast Cancer Interventions: Drug: ATRA; Drug: Toripalimab Sponsors: First Affiliated Hospital of Zhejiang University; Shanghai Longfine Biotechnology Co., Ltd.; TopAlliance Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
Conditions: AML, Adult Interventions: Biological: iPSC-NK cells Sponsors: Zhejiang University; Hangzhou Qihangene Biotech Co.,Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer Interventions: Drug: Alisertib; Drug: Endocrine therapy Sponsors: Puma Biotechnology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
